Thematic Exposure -- 7/10

Quest is one of two players (with Labcorp) controlling the US independent commercial reference-lab channel (>70% combined). #1 in higher-value esoteric/advanced diagnostics (38% of DIS mix). National logistics scale, vast payer contracts, deep EMR connectivity create durable competitive advantages. Oligopoly gate PASS. Held from 8-10 because the total lab market is fragmented (captive hospital/physician-office labs hold majority volume) and the theme grows only mid-single-digit. Weight: 35%

Quest/Labcorp Duopoly -- >70% of Independent Channel

Duopoly Controls the Independent Commercial Reference-Lab Channel

Quest and Labcorp together control >70% of the US independent commercial reference-lab channel. National courier logistics, in-network payer contracts across all major insurers, and deep EMR integration create 12+ month switching costs. A genuine duopoly with high barriers.

Channel Share

>70%

Combined (Quest + Labcorp)

Esoteric/Advanced

In esoteric/advanced diagnostics

Theme Growth

MSD

Mid-single-digit

Switching Cost

12+

Months

Advanced Diagnostics -- Higher-Value Growth Engine

38% of DIS Mix -- Genomic, Molecular, Immunology, and Specialty Testing

Advanced/esoteric diagnostics (38% of DIS mix) is the growth engine -- genomic, molecular, immunology, and specialty testing. Higher reimbursement, less Medicare rate pressure, and faster growth than routine testing.

Total Market Is Fragmented

Captive Hospital Labs and Physician-Office Labs Hold Majority Volume

The caveat: the total US lab market includes captive hospital labs and physician-office labs that hold the majority of test volume. In the total market, Quest's share is lower. Medicare rate regulation constrains pricing on ~54% of the routine test mix.

Oligopoly gate: PASS. Quest + Labcorp >70% of independent channel. #1 in esoteric/advanced.

Data sourced from Daloopa.